Weight loss in people with type 1 diabetes over 12 months: Real-world data comparing tirzepatide, semaglutide and liraglutide.

Al Ozairi E, Irshad M, Alkandari J, Sojan L, Alroudhan D, Alotaibi N, le Roux CW

Diabetes, obesity & metabolism6 Oct 2025Cited by 7 (Europe PMC)

PMID41048008PMCIDPMC12673458DOI10.1111/dom.70172PepBankPUB-41048008

Summary

AimsThis study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m² and type 1 diabetes (T1D).MethodsThis real-world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35), semaglutide (n = 36), liraglutide (n = 97) or usual care (n = 82). Secondary outcomes included changes in lipid profile, renal and liver markers, blood pressure, and HbA1c.ResultsAll three agents led to significant weight loss. Tirzepatide showed the greatest reduction of weight loss (10.9%; p < 0.001), followed by semaglutide (9.9%; p < 0.001) and liraglutide (7.1%; p < 0.001). Dose-dependent reductions were observed for tirzepatide and semaglutide. Tirzepatide, semaglutide and liraglutide modestly reduced HbA1c by 0.65% (p = 0.004), 0.33% (p = 0.034) and 0.23% (p = 0.017), respectively. LDL-cholesterol was reduced by semaglutide (p = 0.05) and liraglutide (p = 0.02), and liraglutide also lowered the urine albumin-to-creatinine ratio (p = 0.007). There was no change in body weight and HbA1c in the usual care group. No severe hypoglycaemia or diabetic ketoacidosis (DKA) events were reported in any group.ConclusionTirzepatide, semaglutide, and liraglutide reduced bodyweight and improved in selected metabolic risk markers over 12 months without increasing the risk for hypoglycaemia or DKA. Weight loss appeared less compared with patients without diabetes. Tirzepatide, semaglutide and liraglutide modestly improved glycaemic control in adults with T1D and obesity. These findings support the potential adjunctive role of GLP-1 receptor agonists in people with obesity and T1D and underscore the need for further validation through randomized controlled trials.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study17

17 results from studies that gave the peptide. 17 results from people.

01HumanObservational studyEfficacy outcome
In people with obesity and type 1 diabetes, liraglutide use was associated with a 0.23% HbA1c reduction over 12 months.
In plain wordsIn people with type 1 diabetes and obesity, liraglutide use was linked to a 0.23% HbA1c reduction.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n = 97
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
HbA1c reduction
0.23%
liraglutide
P value
0.017
liraglutide HbA1c reduction
Source sentences
Summary
Tirzepatide, semaglutide and liraglutide modestly reduced HbA1c by 0.65% (p = 0.004), 0.33% (p = 0.034) and 0.23% (p = 0.017), respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m² and type 1 diabetes (T1D).
Summary · context
This real-world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35), semaglutide (n = 36), liraglutide (n = 97) or usual care (n = 82).
Summary · context
Secondary outcomes included changes in lipid profile, renal and liver markers, blood pressure, and HbA1c.
Show in the study text Report a problemFND-4104800808
02HumanObservational studyEfficacy outcome
In people with obesity and type 1 diabetes, liraglutide use was associated with lower LDL-cholesterol over 12 months.
In plain wordsIn people with type 1 diabetes and obesity, liraglutide use was linked to lower LDL cholesterol.
Peptide
Liraglutide
Outcome
DecreaseLDL-cholesterol
Study
n = 97
Analysis
Secondary
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
P value
0.02
liraglutide LDL-cholesterol reduction
Source sentences
Summary
LDL-cholesterol was reduced by semaglutide (p = 0.05) and liraglutide (p = 0.02), and liraglutide also lowered the urine albumin-to-creatinine ratio (p = 0.007).
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m² and type 1 diabetes (T1D).
Summary · context
This real-world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35), semaglutide (n = 36), liraglutide (n = 97) or usual care (n = 82).
Summary · context
Secondary outcomes included changes in lipid profile, renal and liver markers, blood pressure, and HbA1c.
Show in the study text Report a problemFND-4104800810
03HumanObservational studyEfficacy outcome
In people with obesity and type 1 diabetes, liraglutide use was associated with a lower urine albumin-to-creatinine ratio over 12 months.
In plain wordsIn people with type 1 diabetes and obesity, liraglutide use was linked to a lower urine albumin-to-creatinine ratio.
Peptide
Liraglutide
Outcome
DecreaseUrine albumin-to-creatinine ratio
Study
n = 97
Analysis
Secondary
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
P value
0.007
liraglutide urine albumin-to-creatinine ratio reduction
Source sentences
Summary
LDL-cholesterol was reduced by semaglutide (p = 0.05) and liraglutide (p = 0.02), and liraglutide also lowered the urine albumin-to-creatinine ratio (p = 0.007).
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m² and type 1 diabetes (T1D).
Summary · context
This real-world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35), semaglutide (n = 36), liraglutide (n = 97) or usual care (n = 82).
Summary · context
Secondary outcomes included changes in lipid profile, renal and liver markers, blood pressure, and HbA1c.
Show in the study text Report a problemFND-4104800811
04HumanObservational studyEfficacy outcome
In people with obesity and type 1 diabetes, semaglutide use was associated with a 0.33% HbA1c reduction over 12 months.
In plain wordsIn people with type 1 diabetes and obesity, semaglutide use was linked to a 0.33% HbA1c reduction.
Peptide
Semaglutide
Outcome
DecreaseHbA1c
Study
n = 36
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
HbA1c reduction
0.33%
semaglutide
P value
0.034
semaglutide HbA1c reduction
Source sentences
Summary
Tirzepatide, semaglutide and liraglutide modestly reduced HbA1c by 0.65% (p = 0.004), 0.33% (p = 0.034) and 0.23% (p = 0.017), respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m² and type 1 diabetes (T1D).
Summary · context
This real-world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35), semaglutide (n = 36), liraglutide (n = 97) or usual care (n = 82).
Summary · context
Secondary outcomes included changes in lipid profile, renal and liver markers, blood pressure, and HbA1c.
Show in the study text Report a problemFND-4104800807
05HumanObservational studyEfficacy outcome
In people with obesity and type 1 diabetes, semaglutide use was associated with lower LDL-cholesterol over 12 months.
In plain wordsIn people with type 1 diabetes and obesity, semaglutide use was linked to lower LDL cholesterol.
Peptide
Semaglutide
Outcome
DecreaseLDL-cholesterol
Study
n = 36
Analysis
Secondary
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
P value
0.05
semaglutide LDL-cholesterol reduction
Source sentences
Summary
LDL-cholesterol was reduced by semaglutide (p = 0.05) and liraglutide (p = 0.02), and liraglutide also lowered the urine albumin-to-creatinine ratio (p = 0.007).
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m² and type 1 diabetes (T1D).
Summary · context
This real-world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35), semaglutide (n = 36), liraglutide (n = 97) or usual care (n = 82).
Summary · context
Secondary outcomes included changes in lipid profile, renal and liver markers, blood pressure, and HbA1c.
Show in the study text Report a problemFND-4104800809
06HumanObservational studyEfficacy outcome
In people with obesity and type 1 diabetes, tirzepatide use was associated with a 0.65% HbA1c reduction over 12 months.
In plain wordsIn people with type 1 diabetes and obesity, tirzepatide use was linked to a 0.65% HbA1c reduction.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c
Study
n = 35
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
HbA1c reduction
0.65%
tirzepatide
P value
0.004
tirzepatide HbA1c reduction
Source sentences
Summary
Tirzepatide, semaglutide and liraglutide modestly reduced HbA1c by 0.65% (p = 0.004), 0.33% (p = 0.034) and 0.23% (p = 0.017), respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m² and type 1 diabetes (T1D).
Summary · context
This real-world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35), semaglutide (n = 36), liraglutide (n = 97) or usual care (n = 82).
Summary · context
Secondary outcomes included changes in lipid profile, renal and liver markers, blood pressure, and HbA1c.
Show in the study text Report a problemFND-4104800806
07HumanObservational studyEfficacy outcome
In people with obesity and type 1 diabetes, liraglutide was associated with 7.1% weight loss over 12 months.
In plain wordsIn people with type 1 diabetes and obesity, liraglutide was linked to 7.1% weight loss.
Peptide
Liraglutide
Outcome
DecreaseBody weight loss
Study
n = 97
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Weight loss
7.1%
liraglutide
P value
< 0.001
liraglutide weight loss
Source sentences
Summary
Tirzepatide showed the greatest reduction of weight loss (10.9%; p < 0.001), followed by semaglutide (9.9%; p < 0.001) and liraglutide (7.1%; p < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m² and type 1 diabetes (T1D).
Summary · context
This real-world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35), semaglutide (n = 36), liraglutide (n = 97) or usual care (n = 82).
Summary · context
Secondary outcomes included changes in lipid profile, renal and liver markers, blood pressure, and HbA1c.
Show in the study text Report a problemFND-4104800803
08HumanObservational studySafety outcome
In people with obesity and type 1 diabetes, no severe hypoglycaemia events were reported with liraglutide.
In plain wordsIn people with type 1 diabetes and obesity using liraglutide, no severe hypoglycaemia events were reported.
Peptide
Liraglutide
Outcome
Not applicableSevere hypoglycaemia
Study
n = 97
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
No severe hypoglycaemia or diabetic ketoacidosis (DKA) events were reported in any group.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m² and type 1 diabetes (T1D).
Summary · context
This real-world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35), semaglutide (n = 36), liraglutide (n = 97) or usual care (n = 82).
Summary · context
Secondary outcomes included changes in lipid profile, renal and liver markers, blood pressure, and HbA1c.
Show in the study text Report a problemFND-4104800816
09HumanObservational studySafety outcome
In people with obesity and type 1 diabetes, no diabetic ketoacidosis events were reported with liraglutide.
In plain wordsIn people with type 1 diabetes and obesity using liraglutide, no diabetic ketoacidosis events were reported.
Peptide
Liraglutide
Outcome
Not applicableDiabetic ketoacidosis
Study
n = 97
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
No severe hypoglycaemia or diabetic ketoacidosis (DKA) events were reported in any group.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m² and type 1 diabetes (T1D).
Summary · context
This real-world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35), semaglutide (n = 36), liraglutide (n = 97) or usual care (n = 82).
Summary · context
Secondary outcomes included changes in lipid profile, renal and liver markers, blood pressure, and HbA1c.
Show in the study text Report a problemFND-4104800817
10HumanObservational studyEfficacy outcome
In people with obesity and type 1 diabetes, semaglutide was associated with 9.9% weight loss over 12 months.
In plain wordsIn people with type 1 diabetes and obesity, semaglutide was linked to 9.9% weight loss.
Peptide
Semaglutide
Outcome
DecreaseBody weight loss
Study
n = 36
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Weight loss
9.9%
semaglutide
P value
< 0.001
semaglutide weight loss
Source sentences
Summary
Tirzepatide showed the greatest reduction of weight loss (10.9%; p < 0.001), followed by semaglutide (9.9%; p < 0.001) and liraglutide (7.1%; p < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m² and type 1 diabetes (T1D).
Summary · context
This real-world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35), semaglutide (n = 36), liraglutide (n = 97) or usual care (n = 82).
Summary · context
Secondary outcomes included changes in lipid profile, renal and liver markers, blood pressure, and HbA1c.
Show in the study text Report a problemFND-4104800802
11HumanObservational studyEfficacy outcome
In people with obesity and type 1 diabetes, semaglutide showed dose-dependent weight reductions.
In plain wordsIn people with type 1 diabetes and obesity, semaglutide showed dose-dependent weight reductions.
Peptide
Semaglutide
Outcome
DecreaseDose-dependent body weight reduction
Study
n = 36
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Dose-dependent reductions were observed for tirzepatide and semaglutide.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m² and type 1 diabetes (T1D).
Summary · context
This real-world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35), semaglutide (n = 36), liraglutide (n = 97) or usual care (n = 82).
Summary · context
Secondary outcomes included changes in lipid profile, renal and liver markers, blood pressure, and HbA1c.
Show in the study text Report a problemFND-4104800805
12HumanObservational studySafety outcome
In people with obesity and type 1 diabetes, no severe hypoglycaemia events were reported with semaglutide.
In plain wordsIn people with type 1 diabetes and obesity using semaglutide, no severe hypoglycaemia events were reported.
Peptide
Semaglutide
Outcome
Not applicableSevere hypoglycaemia
Study
n = 36
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
No severe hypoglycaemia or diabetic ketoacidosis (DKA) events were reported in any group.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m² and type 1 diabetes (T1D).
Summary · context
This real-world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35), semaglutide (n = 36), liraglutide (n = 97) or usual care (n = 82).
Summary · context
Secondary outcomes included changes in lipid profile, renal and liver markers, blood pressure, and HbA1c.
Show in the study text Report a problemFND-4104800814
13HumanObservational studySafety outcome
In people with obesity and type 1 diabetes, no diabetic ketoacidosis events were reported with semaglutide.
In plain wordsIn people with type 1 diabetes and obesity using semaglutide, no diabetic ketoacidosis events were reported.
Peptide
Semaglutide
Outcome
Not applicableDiabetic ketoacidosis
Study
n = 36
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
No severe hypoglycaemia or diabetic ketoacidosis (DKA) events were reported in any group.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m² and type 1 diabetes (T1D).
Summary · context
This real-world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35), semaglutide (n = 36), liraglutide (n = 97) or usual care (n = 82).
Summary · context
Secondary outcomes included changes in lipid profile, renal and liver markers, blood pressure, and HbA1c.
Show in the study text Report a problemFND-4104800815
14HumanObservational studyEfficacy outcome
In people with obesity and type 1 diabetes, tirzepatide was associated with 10.9% weight loss over 12 months.
In plain wordsIn people with type 1 diabetes and obesity, tirzepatide was linked to 10.9% weight loss.
Peptide
Tirzepatide
Outcome
DecreaseBody weight loss
Study
n = 35
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Weight loss
10.9%
tirzepatide
P value
< 0.001
tirzepatide weight loss
Source sentences
Summary
Tirzepatide showed the greatest reduction of weight loss (10.9%; p < 0.001), followed by semaglutide (9.9%; p < 0.001) and liraglutide (7.1%; p < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m² and type 1 diabetes (T1D).
Summary · context
This real-world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35), semaglutide (n = 36), liraglutide (n = 97) or usual care (n = 82).
Summary · context
Secondary outcomes included changes in lipid profile, renal and liver markers, blood pressure, and HbA1c.
Show in the study text Report a problemFND-4104800801
15HumanObservational studyEfficacy outcome
In people with obesity and type 1 diabetes, tirzepatide showed dose-dependent weight reductions.
In plain wordsIn people with type 1 diabetes and obesity, tirzepatide showed dose-dependent weight reductions.
Peptide
Tirzepatide
Outcome
DecreaseDose-dependent body weight reduction
Study
n = 35
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Dose-dependent reductions were observed for tirzepatide and semaglutide.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m² and type 1 diabetes (T1D).
Summary · context
This real-world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35), semaglutide (n = 36), liraglutide (n = 97) or usual care (n = 82).
Summary · context
Secondary outcomes included changes in lipid profile, renal and liver markers, blood pressure, and HbA1c.
Show in the study text Report a problemFND-4104800804
16HumanObservational studySafety outcome
In people with obesity and type 1 diabetes, no severe hypoglycaemia events were reported with tirzepatide.
In plain wordsIn people with type 1 diabetes and obesity using tirzepatide, no severe hypoglycaemia events were reported.
Peptide
Tirzepatide
Outcome
Not applicableSevere hypoglycaemia
Study
n = 35
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
No severe hypoglycaemia or diabetic ketoacidosis (DKA) events were reported in any group.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m² and type 1 diabetes (T1D).
Summary · context
This real-world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35), semaglutide (n = 36), liraglutide (n = 97) or usual care (n = 82).
Summary · context
Secondary outcomes included changes in lipid profile, renal and liver markers, blood pressure, and HbA1c.
Show in the study text Report a problemFND-4104800812
17HumanObservational studySafety outcome
In people with obesity and type 1 diabetes, no diabetic ketoacidosis events were reported with tirzepatide.
In plain wordsIn people with type 1 diabetes and obesity using tirzepatide, no diabetic ketoacidosis events were reported.
Peptide
Tirzepatide
Outcome
Not applicableDiabetic ketoacidosis
Study
n = 35
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
No severe hypoglycaemia or diabetic ketoacidosis (DKA) events were reported in any group.
3 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to compare the effects of tirzepatide, semaglutide, and liraglutide on body weight and metabolic risk markers over 12 months in people with body mass index ≥27 kg/m² and type 1 diabetes (T1D).
Summary · context
This real-world study included 250 people with obesity and T1D (female = 54.8%), treated with either tirzepatide (n = 35), semaglutide (n = 36), liraglutide (n = 97) or usual care (n = 82).
Summary · context
Secondary outcomes included changes in lipid profile, renal and liver markers, blood pressure, and HbA1c.
Show in the study text Report a problemFND-4104800813

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
12 Oct 2026, 11:11 UTC
Study results updated
Versions 2 to 3
9 Oct 2026, 03:07 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Weight loss in people with type 1 diabetes over 12 months: Real-world data comparing tirzepatide, semaglutide and liraglutide.

Summary

Results from this study17

Version history

Subjects

Publication types

MeSH terms

Keywords